The Impact of Ethanol Sclerotherapy Before ART Cycle on Cumulative Live Birth Rate in Infertile Women With Endometrioma

What this Trial Is About

Researchers are investigating the effects of ethanol sclerotherapy before assisted reproductive technology (ART) cycles in infertile women with endometrioma. This randomized controlled trial aims to determine whether ethanol sclerotherapy impacts the cumulative live birth rate and other outcomes such as chronic pelvic pain, dysmenorrhea, complications during egg retrieval, response to ovarian stimulation, and pregnancy loss rates. The study focuses on patients with endometrioma sized 4 to 10 cm who are scheduled to undergo ART within two cycles. Participants will be randomly assigned to one of two groups. In the control group, patients will proceed to ART without any intervention before the cycle. In the treatment group, ethanol sclerotherapy will be performed 1 to 2 cycles before ART. This procedure involves aspirating the endometrioma cyst content, washing it with saline, injecting 96% ethanol for 10 minutes, and then aspirating the ethanol. Antibiotics will be given before the procedure to reduce infection risk. Throughout the study, participants will be monitored for outcomes such as the cumulative live birth rate over 18 months and pain scores over 3 months. Assessments include tracking the number of mature eggs retrieved, complications during procedures, and pregnancy loss rates. The study will also consider factors like ovarian reserve measured by anti-Mullerian hormone levels. Participant involvement includes treatment procedures, ART cycles, and follow-up for outcome measurements and safety monitoring.

Ethanol Sclerotherapy Prior to ART